| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/GCC.1183 |
| P698 | PubMed publication ID | 11579459 |
| P50 | author | Brigitte Bressac-de Paillerets | Q43376253 |
| Giovanna Bianchi-Scarrà | Q43376298 | ||
| Florence Demenais | Q56420237 | ||
| Alisa M. Goldstein | Q91400899 | ||
| Marie-Françoise Avril | Q112271024 | ||
| Agnès Chompret | Q114374734 | ||
| Alain Spatz | Q114374763 | ||
| P2093 | author name string | Pascal Joly | |
| Thierry Frebourg | |||
| Carole Rubino | |||
| Danièle Pham | |||
| Stéphane Auroy | |||
| P2860 | cites work | A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 | Q24322196 |
| Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4 | Q27760543 | ||
| Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers | Q28251857 | ||
| A cell cycle regulator potentially involved in genesis of many tumor types | Q28251933 | ||
| Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma | Q28270834 | ||
| Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. | Q30322978 | ||
| Germline p16 mutations in familial melanoma | Q34059915 | ||
| A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families | Q34142079 | ||
| Tumor suppressor p16INK4A: structural characterization of wild-type and mutant proteins by NMR and circular dichroism | Q36813404 | ||
| Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma | Q40019366 | ||
| Functional reassessment of P16 variants using a transfection-based assay | Q40944770 | ||
| Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma | Q40978415 | ||
| Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition | Q41335802 | ||
| Control of pRB phosphorylation | Q41732727 | ||
| Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma | Q44999286 | ||
| CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas | Q47703942 | ||
| Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. | Q54065286 | ||
| A Familial Syndrome of Pancreatic Cancer and Melanoma with a Mutation in theCDKN2Tumor-Suppressor Gene | Q55670980 | ||
| Haplotype analysis of two recurrentCDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations | Q56438205 | ||
| Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941] | Q56893811 | ||
| Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus | Q57269211 | ||
| Mutations in the CDKN2A ( p16INK4a ) gene in microdissected sporadic primary melanomas | Q57664941 | ||
| p16/CDKN2 andCDK4 gene mutations in sporadic melanoma development and progression | Q58200880 | ||
| Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 | Q59082348 | ||
| Characterization of ligurian melanoma families and risk of occurrence of other neoplasia | Q73046674 | ||
| CDKN2A mutations in multiple primary melanomas | Q74357667 | ||
| Genetic aspects of malignant melanoma | Q75968614 | ||
| Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas | Q77919016 | ||
| P433 | issue | 3 | |
| P921 | main subject | founder effect | Q504568 |
| cancer research | Q3421914 | ||
| P304 | page(s) | 195-202 | |
| P577 | publication date | 2001-08-28 | |
| P1433 | published in | Genes, Chromosomes and Cancer | Q5532697 |
| P1476 | title | Sporadic multiple primary melanoma cases:CDKN2Agermline mutations with a founder effect | |
| P478 | volume | 32 |
| Q57499970 | A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families |
| Q38705693 | An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies. |
| Q57744383 | BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma |
| Q37083946 | Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. |
| Q36930013 | Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma |
| Q36365453 | Cutaneous melanoma: family screening and genetic testing |
| Q30375327 | Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. |
| Q34568604 | Genetic and environmental factors in cutaneous malignant melanoma |
| Q35162369 | Genetic epidemiology of melanoma |
| Q34783505 | Genetic insights into familial cancers-- update and recent discoveries |
| Q34203435 | Genetics of melanoma predisposition |
| Q36694476 | Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma |
| Q36147888 | High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families |
| Q36499211 | High- and low-penetrance cutaneous melanoma susceptibility genes. |
| Q39938055 | Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma |
| Q47270996 | Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3. |
| Q34602917 | Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. |
| Q35146540 | Melanoma etiology: where are we? |
| Q42441334 | Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin |
| Q34626994 | New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment. |
| Q79903638 | Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas |
| Q35840024 | Selection criteria for genetic assessment of patients with familial melanoma |
| Q40483208 | The CDKN2A database: Integrating allelic variants with evolution, structure, function, and disease association |
| Q26778756 | Update in genetic susceptibility in melanoma |
| Q79313983 | [CDKN2A gene mutation and loss of p16 protein activity in a patient on levodopa presenting sporadic multiple primary melanoma] |
| Q82637611 | [Genetic and epidemiological aspects of melanoma] |
Search more.